US 11,701,420 B2
Parenteral norovirus vaccine formulations
Charles Richardson, Cambridge, MA (US); Thomas R. Foubert, Cambridge, MA (US); Robert F. Bargatze, Cambridge, MA (US); and Paul Mendelman, Cambridge, MA (US)
Assigned to Takeda Vaccines, Inc., Cambridge, MA (US)
Filed by TAKEDA VACCINES, INC., Cambridge, MA (US)
Filed on Jun. 5, 2020, as Appl. No. 16/894,291.
Application 15/836,030 is a division of application No. 14/796,614, filed on Jul. 10, 2015, granted, now 9,867,876, issued on Jan. 16, 2018.
Application 16/894,291 is a continuation of application No. 15/836,030, filed on Dec. 8, 2017, granted, now 10,675,341.
Application 14/796,614 is a continuation of application No. 13/840,403, filed on Mar. 15, 2013, granted, now 9,801,934, issued on Oct. 31, 2017.
Application 13/840,403 is a continuation of application No. PCT/US2012/046222, filed on Jul. 11, 2012.
Claims priority of provisional application 61/506,447, filed on Jul. 11, 2011.
Prior Publication US 2021/0085778 A1, Mar. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 39/125 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 39/125 (2013.01); A61K 39/39 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/70 (2013.01); C12N 2770/16034 (2013.01)] 21 Claims
 
1. A method of eliciting protective immunity against Norovirus in a human comprising administering parenterally to the human no more than a single dose of a vaccine composition, said composition comprising
(i) genogroup I Norovirus virus-like particles (VLPs), wherein said genogroup I Norovirus VLPs comprise a capsid protein derived from a genogroup I viral strain, or
(ii) genogroup II Norovirus VLPs, wherein said genogroup II Norovirus VLPs comprise a capsid protein derived from a genogroup II viral strain,
wherein said composition induces at least a three-fold increase in Norovirus-specific serum antibody titer as compared to the titer in the human prior to administration of the composition, and
wherein the composition comprises about 5 μg to about 150 μg of said genogroup I or genogroup II Norovirus VLPs.